Cybrexa Therapeutics, an oncology-focused biotechnology company based in New Haven, has appointed pharmaceutical and financial services veteran Stephen Basso to serve as its chief financial officer.
Basso will lead the company’s financial operations, including investor relations and potential financing.
The company is developing anti-tumor therapies for cancer patients. Its lead candidate, CBX-12, is the company’s first to enter the human testing phase. It aims to fight tumors with fewer toxic side effects by depositing powerful cancer-fighting agents directly into tumor cells.
Basso brings more than 30 years of experience in the financial services and pharmaceutical industries. Prior to joining Cybrexa, he had leadership roles at Inozyme Pharma, Alexion Pharmaceuticals and Pfizer.
Per Hellsund, Cybrexa president and CEO, said it is important that the company continue charting CBX-12’s development path.
“With decades of experience in strategic financial planning and analysis in the pharmaceutical industry, Stephen is both a proven talent and a timely addition to Cybrexa,” Hellsund said.
*****
Quantum-Si adds two new directors
Quantum-Si Inc., a Guilford company pioneering next-generation semiconductor chip-based proteomics, recently appointed Marijn Dekkers and Ruth Fattori to its board of directors.
Both have agreed to continue to serve on the board of the combined company following the combination of Quantum-Si and HighCape Capital Acquisition Corp.
Dekkers is former CEO of Bayer AG and Thermo Fisher Scientific, and Fattori is a former executive vice president and chief human resources officer of PepsiCo.
Jonathan Rothberg, founder and chairman of Quantum-Si, said, “Collectively, their skill sets are well positioned to help us navigate this transition as we give the world next-generation protein sequencing.”
Dekkers said the company’s next-generation protein sequencing has the potential for a significant impact on drug discovery, academic research, and diagnostics.
“I look forward to leveraging my experience at Bayer and Thermo Fisher Scientific to help Quantum-Si see its vision through,” Dekkers said.
Fattori is a managing partner of Pecksland Partners LLC where she advises CEOs and senior executives on succession planning, talent development, and other human resources issues.
“I look forward to applying my expertise in building out global organizational functions with an eye on high-caliber talent, diversity, inclusion, and engagement,” Fattori said.
*****
Sachem Capital Corp. appoints new chief investment officer
Sachem Capital Corp. of Branford recently appointed William C. Haydon as its chief investment officer and director of investor relations.
In this new role, Haydon is responsible for managing the company’s liquid reserves and securities portfolio, as well as Sachem’s underwriting team. Haydon also will oversee the company’s investor relations activities.
Haydon is a senior finance and capital markets executive with over 25 years of experience in financial services and investment banking.
Prior to joining Sachem, he served as a portfolio manager and branch manager at Wells Fargo Advisors Financial Network. He has also worked for UBS Financial Services and Northern Mortgage Company LLC.
Sachem CEO John Villano said the company has seen rapid growth and expanded lending activities.
“Bill brings a wealth of experience in areas such as lending and securities asset management, financial strategy and long-term planning,” Villano said. “In addition, he is extremely knowledgeable when it comes to the capital markets, and we look forward to his efforts to help broaden our investor relations activities.”
